# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-053015
Filing Date
2023-04-28
Accepted
2023-04-28 16:22:53
Documents
4
Period of Report
2023-06-22

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm2310546-1_def14a.htm | DEF 14A | 933241
2 | GRAPHIC | px_maxcyteproxy1pg1-bw.jpg | GRAPHIC | 661718
3 | GRAPHIC | px_maxcyteproxy1pg2-bw.jpg | GRAPHIC | 450329
4 | GRAPHIC | sg_mahermasoud-bw.jpg | GRAPHIC | 30301
| Complete submission text file | 0001104659-23-053015.txt |  | 2268276

Mailing Address 22 FIRSTFIELD ROAD SUITE 250 GAITHERSBURG MD 20878
Business Address 22 FIRSTFIELD ROAD SUITE 250 GAITHERSBURG MD 20878 301-517-5556
MAXCYTE, INC. (Filer) CIK: 0001287098 (see all company filings)

EIN.: 522210438 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40674 | Film No.: 23866748
SIC: 8731 Services-Commercial Physical & Biological Research